Analyst recommendations: Qiagen, Skydance, Moderna, PG&E

Moderna and MSD (Merck & Co) released early data for their melanoma vaccine, INTerpath-001, showing a 42% reduction in recurrence or death risk when combined with Keytruda. The study met expectations, with 82.2% recurrence-free survival at 24 months. Shares fell after a data leak but partially recovered. ESMO is investigating the breach. Analysts suggest potential billion-dollar sales if approved.

Merck (MRK) and Moderna (MRNA) reported Phase III trial results showing their cancer vaccine reduced melanoma recurrence or death risk by 42% when combined with pembrolizumab. Overall survival data is not yet mature, requiring further follow-up.

Western Digital reported fiscal Q1 2027 revenue of $4.381B, up 55% YoY, with net income of $1.779B. The company forecasts Q2 revenue of $5.1B, representing 66-72% YoY growth, and raised its dividend by 17%. Management attributed performance to strong demand and pricing.

Moderna (MRNA) shares dropped 17.6% after early data leak from its melanoma vaccine trial with Merck. The vaccine, combined with Keytruda, reduced recurrence or death risk by 42%. Despite positive results, shares fell due to high expectations. UBS and BMO analysts noted strong data but acknowledged inflated expectations. Volume reached 49.9m shares.

Western Digital reported Q1 2027 revenue of $4.38bn, up 55% y-o-y, and adjusted EPS of $4.64, exceeding expectations. Management forecasts Q2 revenue of $5.1bn and adjusted EPS of $5.80. Despite strong results, the stock remained flat in after-hours trading due to concerns about pricing power and competition.

Moderna and Merck's personalized mRNA cancer vaccine, combined with Merck's Keytruda, reduced melanoma recurrence or death risk by 42% in a Phase 3 trial with 1,100+ patients. Two-year recurrence-free rates were 82.2% with the vaccine vs. 70% with Keytruda alone. The companies aim for US approval by 2027 and are testing the treatment in other cancers.